Stoke Therapeutics, Inc. (NASDAQ:STOK) is anticipated to surpass Wall Street earnings estimates in its upcoming quarterly report.
The company has demonstrated consistent revenue growth, with a significant increase reported in the previous quarter.
Despite a negative P/E ratio, STOK maintains a strong liquidity position and minimal reliance on debt financing.
Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company based in Bedford, Massachusetts. It focuses on developing RNA medicines to restore protein expression, with a key product being zorevunersen, an investigational treatment for Dravet syndrome. Operating in the Zacks Medical – Biomedical and Genetics industry, STOK is set to release its quarterly earnings on March 24, 2025.
Wall Street estimates STOK’s earnings per share (EPS) to be -$0.56, with projected revenue of approximately $4.28 million. However, the company has a history of surpassing expectations. In the previous quarter, STOK reported a loss of $0.18 per share, significantly better than the Zacks Consensus Estimate of a $0.51 loss, achieving a 64.71% earnings surprise.
STOK’s revenue performance has also been impressive. For the quarter ending December 2024, the company reported $22.61 million in revenue, exceeding the Zacks Consensus Estimate by 483.59%. This marked a substantial increase from the $2.8 million reported in the same quarter the previous year, showcasing consistent revenue growth over the past four quarters.
Despite a negative price-to-earnings (P/E) ratio of -4.94, STOK maintains a strong liquidity position with a current ratio of approximately 5.81. This indicates that the company has ample short-term assets to cover its short-term liabilities. Additionally, STOK has a low debt-to-equity ratio of 0.01, reflecting minimal reliance on debt financing.
Investors are keenly watching STOK’s upcoming earnings report, as the company is anticipated to surpass earnings estimates once again. The sustainability of any immediate price change and future earnings expectations will largely depend on the management’s discussion of business conditions during the earnings call.
